INTRODUCTION
ICH E10: Choice of Control Group in Clinical Trials, hereafter referred to as E10, was written as a follow-on document to ICH E9 [1] . Its primary purpose was to provide a comprehensive review of all types of controls that could be used in clinical trials; however, it is most well known for its discussions of 'non-inferiority (NI) designs' (a term coined in ICH E9), and its introduction of the terms 'assay sensitivity' and 'historical sensitivity to drug effects' into the clinical trial lexicon. Although it is true that much of the motivation was to better define the characteristics of the NI trials, ironically this only occupies 2.5 pages of a 30-page document. Although it created a common language for the discussion of such trials, it did leave some of the critical issues (e.g., choice of margin) unresolved and as such has led to some significant controversy over the use of such designs in the approval of new drugs [2] . As such, it has not been as widely accepted as a successful teaching tool as was the case for ICH E9, as noted in a companion article [3] .
The purpose of this viewpoint is to acknowledge the successes and issues around the use of E10 since its inception 10 years ago and make recommendations on the way forward.
GEOGRAPHIC IMPACT
E10 achieved several important purposes globally. It brought to light the inherent complexities in selecting a control group for clinical trials, especially in situations where a placebo control might be considered unethical. What the guideline reflected was a drive for more active controlled trials to demonstrate the superiority of new drugs in a move to get away from the 'me-too' era. The drive for the use of active controls has long been a focus of European and Japanese regulators for this reason, whereas the US FDA was far more focused on the use of placebo trials. Thus in the true spirit of ICH, E10 tried to bring together potentially disparate views of the design of trials.
The use in E10 of safety trials was actively discussed at the time of the writing of the document, but, as noted in the next section, the concept is now taking hold, and perhaps in the future we may see combination designs of superiority or NI for efficacy, and NI for safety! The creation of a common language spawned a number of regulatory guidance documents and international publications, including a recent review in China [4] . The debate will undoubtedly be renewed when the draft of the FDA Guidance on NI trials is finalized [5] .
Some of the aforementioned controversy about NI trials is that new treatments were sometimes shown to be non-inferior to active controls of marginal initial efficacy. The actual effect of each successive new treatment may shrink to zero as the margins got slowly closer to NI to placebo. The term 'bio-creep' was introduced to define this phenomenon [6] . If the spirit of the NI approach was implemented, and one compared the new treatment to the best available treatment, then such trials would quickly become difficult to run as the margins would shrink for new treatments.
SCIENTIFIC IMPACT OF ICH -E10
First and foremost, E10 was the foundation for regulatory guidance issued by both FDA and EMA
Q1
on the topic of NI trials [7] [8] [9] . Though E10 discusses NI trials, and the clinical and statistical literature is replete with publications covering this topic, resolution of major issues with NI trials has not been obtained. The FDA draft guidance of March 2010, for example, recommends that the fixed margin method be used to design and analyze the data from a NI trial (ref ) . The FDA's recommendation has been called into question by industry statisticians who defend the use of the synthetic method to control the Type 1 error rate associated with the NI null hypothesis [10, 11] . Though E10 discusses the use of a fixed margin, it does not discuss data analysis methodologies. Analysis of a fixed-margin design will control the Type 1 error rate for that study alone. In contrast, the synthetic method uses both the historical data from the placebo-controlled studies ( which purport to demonstrate that the current control is in fact 'active'), and the data from the current active controlled study to determine NI, controlling the Type 1 error rate across all these studies [12] [13] [14] .
Though E10 states that most active-controlled trials are NI trials, this assumption 01  63  02  64  03  65  04  66  05  67  06  68  07  69  08  70  09  71  10  72  11  73  12  74  13  75  14  76  15  77  16  78  17  79  18  80  19  81  20  82  21  83  22  84  23  85  24  86  25  87  26  88  27  89  28  90  29  91  30  92  31  93  32  94  33  95  34  96  35  97  36  98  37  99  38  100  39  101  40  102  41  103  42  104  43  105  44  106  45  107  46  108  47  109  48  110  49  111  50  112  51  113  52  114  53  115  54  116  55  117  56  118  57  119  58  120  59  121  60  122  61  123  62  124 F. W. Rockhold and G. Enas comparative effectiveness studies seeking to demonstrate superior outcomes. There are a number of reasons that more superiority studies are being conducted using an active control. In many life-threatening or seriously morbid conditions when approved therapies are available, it is often viewed as unethical to test single agent therapy against a (putative) placebo. Investigators either have to resort to add-on treatment comparisons, or head to head versus the approved therapy. Likewise, in conditions where placebo studies have typically been used, there is a growing need from many stakeholders, prescribers and payers included, to know which of multiple therapies is best for a condition. Placebo controlled studies don't provide that information and comparative effectiveness superiority studies are necessary. A broader concern about benefit-risk comparisons across a pharmacologic class or other alternatives has produced a driving need for large active controlled studies. To answer the question 'which one is best' requires that one demonstrate the superiority of at least one of the drugs under study relative to overall benefit-risk. However, NI is often a legitimate additional goal of these studies, and E10 has provided the impetus for thoughtful design and analysis of these often large and expensive studies. E10 will continue to guide development of these 'gold-standard' randomized, controlled trials even as observational database studies are becoming more prevalent to answer 'what should I prescribe or pay for' types of questions. E10 has forced investigators to be much more rigorous and thoughtful about a number of statistical issues associated with NI studies [15] [16] [17] . In particular, the twin topics of assay sensitivity and constancy of effect were discussed extensively and remain the bedrock concerns with NI trials. Assay sensitivity requires that the current study be capable of differentiating the experimental and active control if experimental was in fact inferior to active control Likewise, the constancy assumption requires that the relationship between active control and placebo is reliably estimated from historical studies. These are the assumptions that must be made when the current study is conducted without a placebo control group. These issues are manifested in a number of different topics that E10 forces one to consider, including:
U N C O R R E C T E D P R O O F
Hypothesis testing framework with appropriate null and alternative hypotheses under a nested family of tests [18, 19] Establishment of the fixed margin based on estimation of active-control effect from multiple historical studies [20, 21] Minimization of 'bias towards no-difference' resulting from non-adherence, treatment withdrawal, missing data, protocol deviations, and 'bio-creep' [6, 22] Appropriate patient population to analyze (e.g., Intent-to-treat versus Per-Protocol) [23] Study designs with active and placebo controls [24] The literature is starting to be populated with case studies showing how these issues are being addressed by regulatory agencies [25] . Much of this effort has been within the regulatory agencies and has facilitated scientific discussion between sponsors and regulators. NI trials have often been held to public scrutiny as they form the basis for significant applications for marketing approval.
Likewise, E10 has spawned a whole new conversation regarding the demonstration of safety or establishment of 'no harm' . In this situation, one desires to demonstrate NI with an 'inactive' or 'safe' control (e.g., placebo). The recent FDA guidance on cardiovascular risk assessment for drugs intended to treat patients with Type 2 diabetes is an example [26] . One must rule out an unacceptably high incidence of risk. In this case, the FDA has established by fiat what the fixed margin should be both prior to and following market authorization. Pre-market demonstration of similarity to a putatively safe agent will typically be based on a meta-analysis of all evidence from the Phase 3 trials contained in the new drug application. Post-market safety will usually require a dedicated cardiovascular outcomes study showing NI (if not superiority) with placebo or a marketed agent.
CONCLUSION
ICH E10 helped create common language around the design of randomized controlled clinical trials, with an emphasis on active controlled trials. Although it did not deal with all the issues, it did create the infrastructure and language for the debate and numerous spinoff documents have been created. Because of the number of issues being currently debated, an update of the document does not make sense at this time. We can look forward to the resolution of the issues of margin and choice of which active control to use, and once some consensus has been achieved, create a parallel ICH guidance. In spite of the inherent complexities of these designs, it is likely that the use of NI designs will continue for its use in safety trials and as placebo designs become more and more difficult to execute. Thus continued perseverance to solve these issues is essential.
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